Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study

Open access
Choi, Yoon Young, Kim, Hyunki, Shin, Su-Jin, Kim, Ha Yan, Lee, Jinae, Yang, Han-Kwang, Kim, Woo Ho, Kim, Young-Woo, Kook, Myeong-Cherl, Park, Young Kyu, Kim, Hyung-Ho, Lee, Hye Seung, Lee, Kyung Hee, Gu, Mi Jin, Choi, Seung Ho, Hong, SoonWon, Kim, Jong Won, Hyung, Woo Jin, Noh, Sung Hoon, Cheong, Jae-Ho·2019·Annals of Surgery

Abstract

Objective: We investigated microsatellite instability (MSI) status and programed cell death ligand 1 (PD-L1) expression as predictors of prognosis and responsiveness to chemotherapy for stage II/III gastric cancer. Background: The clinical implications of MSI status and PD-L1 expression in gastric cancer have not been well-elucidated. Methods: Tumor specimens and clinical information were collected from patients enrolled in the CLASSIC trial—a randomized controlled study of capecitabine plus oxaliplatin-based adjuvant chemotherapy. Five quasi-monomorphic mononucleotide markers were used to assess tumor MSI status. PD-L1 expressions of tumor and stromal immune cells were evaluated using immunohistochemistry. Results: Of 592 patients, 40 (6.8%) had MSI-high (MSI-H) tumors. Among 582 patients available for immunohistochemistry evaluation, PD-L1 was positive in tumor cells (tPD-L1) of 16 patients (2.7%) and stromal immune cells (sPD-L1) of 165 patients (28.4%). Multivariable analysis of disease-free survival (DFS) showed that MSI-H and sPD-L1-positivity were independent prognostic factors [hazard ratio 0.301 (0.123–0.736), 0.714 (0.514–0.991); P = 0.008, 0.044), as were receiving chemotherapy, age, tumor grade, and TNM stage. Although adjuvant chemotherapy improved DFS in the microsatellite-stable (MSS) group (5-year DFS: 66.8% vs 54.1%; P = 0.002); no benefit was observed in the MSI-H group (5-year DFS: 83.9% vs 85.7%; P = 0.931). In the MSS group, sPD-L1-negative patients, but not sPD-L1-positive patients, had significant survival benefit from adjuvant chemotherapy compared with surgery only (5-year DFS: 66.1% vs 50.7%; P = 0.001). Conclusion: MSI status and PD-L1 expression are clinically actionable biomarkers for stratifying patients and predicting benefit from adjuvant chemotherapy after D2 gastrectomy for stage II/III gastric cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0000000000002803

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 239

Metadata

Authors
Choi, Y. Y., Kim, H., Shin, S.-J., Kim, H. Y., Lee, J., Yang, H.-K., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y. K., Kim, H.-H., Lee, H. S., Lee, K. H., Gu, M. J., Choi, S. H., Hong, S., Kim, J. W., Hyung, W. J., Noh, S. H., & Cheong, J.-H.
Venue
Annals of Surgery
Published
2019-08
Volume
270
Issue
2
Pages
309-316
ISSN
  • 0003-4932 (ISSN-L)
  • 1528-1140
OpenAlex
W2802927766
Cited by
239
References
9
FWCI
17.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. https://app.cochat.ai/papers/10.1097/sla.0000000000002803
The paper
Choi, Y. Y., Kim, H., Shin, S.-J., Kim, H. Y., Lee, J., Yang, H.-K., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y. K., Kim, H.-H., Lee, H. S., Lee, K. H., Gu, M. J., Choi, S. H., Hong, S., Kim, J. W., Hyung, W. J., Noh, S. H., & Cheong, J.-H. (2019). Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Annals of Surgery. https://doi.org/10.1097/sla.0000000000002803

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.